CHICAGO – Gastroesophageal reflux disease may constitute a heretofore unrecognized risk factor for coronary heart disease.
In a nationwide case-control study of prodigious proportions,...
Communication and collaborative use of technology by physicians who serve underserved populations and by specialists can enhance patient management and treatment of hepatitis C virus infection,...
CHICAGO – Several medical societies recommend that patients with cirrhosis undergo ultrasound surveillance for hepatocellular carcinoma every 6 months, but studies suggest less than 20% receive...
CHICAGO – Gastroesophageal reflux disease may constitute a heretofore unrecognized risk factor for coronary heart disease.
In a nationwide case-control study of prodigious proportions,...
CHICAGO – Gastroesophageal reflux disease may constitute a heretofore unrecognized risk factor for coronary heart disease.
In a nationwide case-control study of prodigious proportions,...
CHICAGO – The investigational ghrelin agonist RM-131 significantly improved gastric emptying and vomiting in patients with diabetic gastroparesis in a phase II, double-blind study.
Gastric emptying...
CHICAGO – The investigational ghrelin agonist RM-131 significantly improved gastric emptying and vomiting in patients with diabetic gastroparesis in a phase II, double-blind study.
Gastric emptying...
CHICAGO – Two old workhorses in the treatment of hepatitis C are being put out to pasture – interferon and ribavirin.
Newer, less toxic oral regimens can cure more patients with fewer side effects,...
CHICAGO – Two old workhorses in the treatment of hepatitis C are being put out to pasture – interferon and ribavirin.
Newer, less toxic oral regimens can cure more patients with fewer side effects,...
CHICAGO – The oral drug duo of sofosbuvir and ribavirin produced good cure rates in a study of 419 patients with hepatitis C genotype 2 or 3.
Dr. Bruce R. Bacon, who was not involved in the study,...